The role of adjuvant chemotherapy for patients with resected pancreatic cancer: Systematic review of randomized controlled trials and meta-analysis

Oncology

Volumn 72, Issue 5-6, 2008, Pages 314-321

  Boeck, Stefan ^a   Ankerst, Donna Pauler ^b   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adjuvant chemotherapy; Chemoradiation; Meta analysis; Pancreatic cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 39049173392     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113054     Document Type: Article

References (30)

1. Ozols RF, Herbst RS, Colson YL, et al: Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2007;25:146-162.
2. Beger HG, Rau B, Gansauge F, et al: Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003;27:1075-1084.
3. Cress RD, Yin D, Clarke L, et al: Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006;17:403-409.
4. Alexakis N, Halloran C, Raraty M, et al: Current standards of surgery for pancreatic cancer. Br J Surg 2004;91:1410-1427.
5. Karpoff HM, Klimstra DS, Brennan MF, et al: Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 2001;136:44-47.
6. Lüttges J, Vogel I, Menke M, et al: The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchow Arch 1998;433:237-242.
7. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 2007;297:267-277.
8. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: analysis and examples (II). Br J Cancer 1977;35:1-39.
9. Cooper H, Hedges LV: The Handbook of Research Synthesis. New York, Russell Sage Foundation, 1994, pp 231-284.
10. Bakkevold KE, Arnesjø B, Dahl O, et al: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater - results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993;29:698-703.
11. Kosuge T, Kiuchi T, Mukai K, et al: A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006;36:159-165.
12. Takada T, Amano H, Yasuda H, et al: Is post-operative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685-1695.
13. Neoptolemos JP, Dunn JA, Stocken DD, et al: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001;358:1576-1585.
14. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
15. Stocken DD, Büchler MW, Dervenis C, et al: Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005;92:1372-1381.
16. Khanna A, Walker GR, Livingstone AS, et al: Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg 2006;10:689-697.
17. Hochster HS, Haller DG, De Gramont A, et al: Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006;107:676-685.
18. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
19. Gastrointestinal Tumour Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006-2010.
20. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-784.
21. Regine WF, Winter KW, Abrams R, et al: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma (abstract 4007). J Clin Oncol 2006;24:180s.
22. Blackstock AW, Mornex F, Partensky C, et al: Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer 2006;95:260-265.
23. Wilkowski R, Thoma M, Duhmke E, et al: Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;58:768-772.
24. Knaebel HP, Märten A, Schmidt J, et al: Phase III trial of postoperative cisplatin, interferon α-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI: study protocol. BMC Cancer 2005;5:37-44.
25. Crane CH, Ellis LM, Abbruzzese JL, et al: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006;24:1145-1151.
26. Boeck S, Stieber P, Holdenrieder S, et al: Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006;70:255-264.
27. Ferrone CR, Finkelstein DM, Thayer SP, et al: Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897-2902.
28. Berger AC, Winter K, Hoffmann J, et al: Post-resection CA 19-9 predicts overall survival (OS) in patients treated with adjuvant chemoradiation: A secondary endpoint of RTOG 9704 (abstract 4522). J Clin Oncol 2007;25:203s.
29. Neoptolemos JP, Stocken DD, Dunn JA, et al: Influence of resection margins on survival for patients with pancreatic cancer treated with adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-768.
30. Verbeke CS, Leitch D, Menon KV, et al: Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232-1237.